A vitamin D drug showed responses in pancreatic tumors rich in its receptor

Ten of the 24 people with untreated metastatic pancreatic cancer who received the vitamin D analog paricalcitol alongside chemotherapy had a partial response, against one of 12 on chemotherapy plus placebo. The trial enrolled only 36 patients in total, and its main job was to test safety. The sharper signal sat in a smaller slice of that group: patients whose tumors carried high levels of the vitamin D receptor.

Brian Wolpin and Kimberly Perez of Dana-Farber Cancer Institute led the work, with Ronald Evans of the Salk Institute, whose preclinical work had predicted that engaging the receptor would dampen the dense fibrotic tissue that shields pancreatic tumors from treatment. The results appeared in Nature Cancer on May 25, 2026, and were reposted on September 30, which is when many readers met them.

Paricalcitol and the three trial arms

Paricalcitol is a synthetic form of vitamin D that binds the vitamin D receptor. According to the Salk Institute’s release, the 36 patients were divided into three groups of 12: gemcitabine plus nab-paclitaxel with a placebo, the same chemotherapy with intravenous paricalcitol, and the same chemotherapy with oral paricalcitol. Every participant had metastatic disease and no earlier treatment for it. The study is registered as NCT03520790. Placebo-controlled randomization matters here because pancreatic cancer outcomes vary widely between patients, so even a pilot with a comparison arm is easier to interpret than a single-arm series. The three arms ran in parallel at equal size, 12 patients each, so the intravenous and oral routes were each set against the same placebo group of 12 rather than against a historical comparison.

The Nature Cancer abstract, as summarized by France’s national cancer institute, calls it a randomized, multiarm, run-in phase study whose primary endpoint was the safety of adding the receptor agonist to first-line chemotherapy. Biopsies taken during treatment showed fewer activated fibroblasts, the cells that build the protective stroma, and more CD8-positive T cells moving into the tumor in the paricalcitol arms.

Response rates and the receptor subgroup

Pooled across both paricalcitol arms, partial responses occurred in 10 of 24 patients, or 42 percent, compared with 1 of 12, or 9 percent, on placebo. Five paricalcitol patients were free of progression at one year, and none of the placebo patients were. Those figures describe everyone who received the drug, not only those with receptor-rich tumors, and with groups this small a shift of two or three patients moves the percentages a long way. A partial response means tumors shrank on scans by a predefined amount; it does not mean the cancer disappeared, and it is a different measurement from how long patients lived. The survival statement in the release applies only to the receptor-high group and is not reported as a hazard ratio or median in the material Salk and Dana-Farber published.

The receptor finding is narrower. In the Dana-Farber release, the institute states that patients with high vitamin D receptor levels who received paricalcitol “had better responses to chemotherapy and the longest overall survival time following treatment.” Neither release gives the number of patients in that subgroup or a response rate for it, so the size of the advantage cannot be read from them. The abstract says only that receptor protein expression predicted response among patients receiving paricalcitol.

Limits built into a 36-patient pilot

Dana-Farber describes the study as a pilot not designed to compare how well the treatments work, and a trial of 36 people split three ways cannot settle that. Ecancer’s account adds that larger studies are needed and that the receptor measurement still has to be validated as a way to choose patients. No regulator has approved paricalcitol for pancreatic cancer.

Safety was mixed. Paricalcitol was given safely with chemotherapy overall, but five of the 12 oral patients developed elevated calcium, graded 2 to 4, and needed lower doses. Calcium is the practical ceiling on vitamin D analogs.

Current options explain the interest in an add-on drug at all. The National Cancer Institute’s clinician summary calls exocrine pancreatic cancer rarely curable, with an overall survival rate under 6 percent. Evans framed the aim as using the body’s own dampening system for fibrosis and inflammation “to enable other therapies to do their job.”

The trial registry entry and the journal paper are the places to look for the subgroup count; neither release prints it, and the abstract summary reviewed here does not either. Until that number is public, the receptor result reads as a pointer for the next trial, not a measured effect size.

A follow-up would need to select patients by receptor level in advance and measure survival as its primary result. The current data cannot say whether high receptor levels identify who benefits or simply travel with a handful of patients who did well, and the subgroup size that would decide it is absent from both releases.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview